Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

RadNet joins Alzheimer’s biomarker study
August 2014
SHARING OPTIONS:

LOS ANGELES—RadNet Inc. has joined the Imaging and Genetic Biomarkers for Alzheimer’s Disease (ImaGene) study, a six-year long observational biomarker study launched in 2008 by the UCLA- Easton Center that seeks to investigate the interaction between genes, proteins, amyloid positron emission tomography (PET) imaging and MRI brain imaging in aging and the prodromal stages of Alzheimer’s disease. Vizamyl (Flutemetamol F18), a radioactive tracer used in PET imaging of the brain, will be used in support of the study to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment. Patients who meet the study’s criteria will undergo a PET/CT scan with Vizamyl at a RadNet radiology facility. The study is supported by GE Healthcare and sponsored by the Jim Easton Consortium for Alzheimer’s Disease Drug Discovery and Biomarkers and the National Institute of Aging.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.